A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
Open Access
- 18 May 2020
- journal article
- review article
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- Vol. 32 (7) , 13-25
Abstract
Background: In December 2019, the pneumonia outbreak reported in Wuhan, Hubei Province, China. WHO introduced a novel coronavirus and the virus named Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) in January 2020. There are not any specific antiviral agents for coronavirus disease 19 (COVID‐19). Objective: Our review aimed to discuss treatment options and the efficacy of currently prescribed drugs and supportive care in COVID‐19 patients. Study Design: A literature review of the articles in the Web of Science, PubMed, Scopus and EMBASE conducted. Results: Lopinavir/ritonavir combination was the most frequently used drug, followed by Arbidol and Oseltamivir and Methylprednisolone. Lopinavir/Ritonavir outcome showed the fever and respiratory infection improve in day two and day eight, respectively. Also, negative PCR of SARS‐CoV‐2 in days six and 7day was seen and finally these patients discharged in 10 days. Conclusions: Lopinavir/Ritonavir was the most improving administrated antiviral combination, which might be a good option for COVID-19 due to its availability. Although supportive care such as O2 supplementary and IV fluid therapy has improved outcomes. There are not evidence for suggesting a new treatment or a new drug, which mean the necessity of further investigations for drug research in a clinical trial for a conclusion about the optimum treatment.Keywords
This publication has 48 references indexed in Scilit:
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitroAntiviral Research, 2020
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitroAntiviral Research, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic targetIntensive Care Medicine, 2020
- A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment optionJournal of Medical Virology, 2020
- The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019Journal of Medical Virology, 2020
- Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple CasesVirologica Sinica, 2020
- Deducing the Crystal Structure of MERS-CoV Helicase2019
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto AreaJAMA, 2003